A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence
In this study the study sponsor, Polynoma LLC, is testing a cancer vaccine called Seviprotimut-L, to determine its safety and effectiveness in delaying the recurrence of melanoma.
The condition being studied is melanoma of the skin.
To be eligible for this study you must have had a confirmed stage IIB, IIC, or III melanoma that has been surgically removed and be 18 years of age or older.
18 - 80
Healthy Volunteers Needed
Duration of Participation
This study will take 15 clinic visits and 2 years to complete.
call Liz Stoos at 503-418-9386 or e-mail firstname.lastname@example.org
11230 Sorrento Valley Road, Suite 215
San Diego, CA 92121